Testing Pasritamig Before Surgery for the Treatment of Localized Prostate Cancer

Summary

This phase I trial tests the safety and feasibility of giving pasritamig before surgery in patients with unfavorable intermediate-risk, high-risk, or very high-risk localized prostate cancer. Pasritamig is a bispecific antibody that works by bringing immune cells called T cells close to prostate cancer cells that express KLK2, which may help the immune system attack the cancer. Giving pasritamig before radical prostatectomy may help researchers determine how the drug affects prostate cancer and the immune cells within the tumor.

Timeline

Start

2026-11-30

Primary completion

2028-11-30

Completion

2028-11-30

Drugs

Indications